Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 19-20/2015

01.10.2015 | main topic

The role for surgeryin high-risk prostate cancer

verfasst von: Cécilia Lanchon, Shahrokh F. Shariat, Morgan Rouprêt, MD, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 19-20/2015

Einloggen, um Zugang zu erhalten

Summary

High-risk prostate cancer (PCa) refers to a very heterogeneous subgroup of disease. Recent series have shown very promising results of radical prostatectomy (RP)—alone or part as a multimodality approach—in patients with high-risk PCa, with satisfactory survival curves even though biochemical recurrence rate was high. Adjuvant treatment (radiotherapy (RT) alone or combined with androgen deprivation) was necessary in 20 to 54 % of patients, notably in cases with positive surgical margins. As for functional outcomes, urinary continence was preserved in about 92 % of cases and overall potency in 60 %. When comparing RP versus RT as primary treatment for high-risk PCa, a recent meta-analysis found surgery to be associated with an improved cancer-specific mortality compared with RT. In selected high-risk PCa young patients, surgery appears to be a valid option. Patients should however be informed of the possibility of adjuvant treatment, as part of a multimodal approach.
Literatur
1.
Zurück zum Zitat Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.CrossRefPubMed Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.CrossRefPubMed
2.
Zurück zum Zitat Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.CrossRefPubMed Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.CrossRefPubMed
3.
Zurück zum Zitat Salomon L, Bastide C, Beuzeboc P, et al. [CCAFU recommendations 2013: prostate cancer]. Prog Urol. 2013;23 Suppl 2:69–101.CrossRef Salomon L, Bastide C, Beuzeboc P, et al. [CCAFU recommendations 2013: prostate cancer]. Prog Urol. 2013;23 Suppl 2:69–101.CrossRef
4.
Zurück zum Zitat Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53(5):950–9.PubMedCentralCrossRefPubMed Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53(5):950–9.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat D’Amico AV, Desjardin A, Chung A, et al. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer. 1998;82(10):1887–96.CrossRefPubMed D’Amico AV, Desjardin A, Chung A, et al. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer. 1998;82(10):1887–96.CrossRefPubMed
6.
Zurück zum Zitat Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8(2):162–200.PubMed Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8(2):162–200.PubMed
7.
Zurück zum Zitat Algarra R, Zudaire B, Tienza A, et al. Optimizing D’Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data. Actas Urol Esp. 2014;38(9):594–9.CrossRefPubMed Algarra R, Zudaire B, Tienza A, et al. Optimizing D’Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data. Actas Urol Esp. 2014;38(9):594–9.CrossRefPubMed
8.
Zurück zum Zitat Thompson J, Lawrentschuk N, Frydenberg M, Thompson L, Stricker P. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int. 2013;112 Suppl 2:6–20.CrossRefPubMed Thompson J, Lawrentschuk N, Frydenberg M, Thompson L, Stricker P. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int. 2013;112 Suppl 2:6–20.CrossRefPubMed
9.
Zurück zum Zitat Renard-Penna R, Roupret M, Comperat E, et al. Accuracy of high resolution (1.5 T) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: results from a prospective study. Urol Oncol. 2013;31(4):448–54.CrossRefPubMed Renard-Penna R, Roupret M, Comperat E, et al. Accuracy of high resolution (1.5 T) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: results from a prospective study. Urol Oncol. 2013;31(4):448–54.CrossRefPubMed
10.
Zurück zum Zitat Briganti A, Chun FK, Salonia A, et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol. 2007;51(1):112–9. (discussion 119–120).CrossRefPubMed Briganti A, Chun FK, Salonia A, et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol. 2007;51(1):112–9. (discussion 119–120).CrossRefPubMed
11.
Zurück zum Zitat Mearini L, Nunzi E, Bini V, Lepri L, Bruno R, Porena M. Radical prostatectomy in high-risk prostate cancer: incidence of specimen-confined disease (pT2-pT3a N0R0) and outcomes. Urologia. 2014;81(2):125–32.CrossRefPubMed Mearini L, Nunzi E, Bini V, Lepri L, Bruno R, Porena M. Radical prostatectomy in high-risk prostate cancer: incidence of specimen-confined disease (pT2-pT3a N0R0) and outcomes. Urologia. 2014;81(2):125–32.CrossRefPubMed
12.
Zurück zum Zitat Roumiguie M, Beauval JB, Filleron T, et al. External validation of the Briganti nomogram to estimate the probability of specimen confined disease in patients with high-risk prostate cancer. BJU Int. 2014;114(6b):E113–9.CrossRefPubMed Roumiguie M, Beauval JB, Filleron T, et al. External validation of the Briganti nomogram to estimate the probability of specimen confined disease in patients with high-risk prostate cancer. BJU Int. 2014;114(6b):E113–9.CrossRefPubMed
13.
Zurück zum Zitat Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology. 2007;69(6):1170–5.CrossRefPubMed Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology. 2007;69(6):1170–5.CrossRefPubMed
14.
Zurück zum Zitat Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol. 2007;51(1):121–8. (discussion 128–9).CrossRefPubMed Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol. 2007;51(1):121–8. (discussion 128–9).CrossRefPubMed
15.
Zurück zum Zitat Ploussard G, Salomon L, Allory Y, et al. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer. BJU Int. 2010;106(1):86–90.CrossRefPubMed Ploussard G, Salomon L, Allory Y, et al. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer. BJU Int. 2010;106(1):86–90.CrossRefPubMed
16.
Zurück zum Zitat Yamamoto S, Kawakami S, Yonese J, et al. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy. Jpn J Clin Oncol. 2012;42(6):541–7.CrossRefPubMed Yamamoto S, Kawakami S, Yonese J, et al. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy. Jpn J Clin Oncol. 2012;42(6):541–7.CrossRefPubMed
17.
Zurück zum Zitat Nguyen K, Eltz S, Drouin SJ, et al. Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. World J Urol. 2009;27(5):653–8.CrossRefPubMed Nguyen K, Eltz S, Drouin SJ, et al. Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. World J Urol. 2009;27(5):653–8.CrossRefPubMed
18.
Zurück zum Zitat Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol. 2010;58(1):1–7. (discussion 10–11).CrossRefPubMed Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol. 2010;58(1):1–7. (discussion 10–11).CrossRefPubMed
19.
Zurück zum Zitat Pokala N, Trulson JJ, Islam M. Long-term outcome following radical prostatectomy for Gleason 8–10 prostatic adenocarcinoma. World J Urol. 2014;32(6):1385–92.CrossRefPubMed Pokala N, Trulson JJ, Islam M. Long-term outcome following radical prostatectomy for Gleason 8–10 prostatic adenocarcinoma. World J Urol. 2014;32(6):1385–92.CrossRefPubMed
20.
Zurück zum Zitat Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):869–75.PubMedCentralCrossRefPubMed Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):869–75.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572–8.CrossRefPubMed Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572–8.CrossRefPubMed
22.
Zurück zum Zitat Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296(19):2329–35.CrossRefPubMed Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296(19):2329–35.CrossRefPubMed
23.
Zurück zum Zitat Murphy DG, Kerger M, Crowe H, Peters JS, Costello AJ. Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy: 400 cases with a minimum of 12 months follow-up. Eur Urol. 2009;55(6):1358–66.CrossRefPubMed Murphy DG, Kerger M, Crowe H, Peters JS, Costello AJ. Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy: 400 cases with a minimum of 12 months follow-up. Eur Urol. 2009;55(6):1358–66.CrossRefPubMed
24.
Zurück zum Zitat Petrelli F, Vavassori I, Coinu A, Borgonovo K, Sarti E, Barni S. Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis. Clin Genitourin Cancer. 2014;12(4):215–24.CrossRefPubMed Petrelli F, Vavassori I, Coinu A, Borgonovo K, Sarti E, Barni S. Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis. Clin Genitourin Cancer. 2014;12(4):215–24.CrossRefPubMed
25.
Zurück zum Zitat Abdollah F, Schmitges J, Sun M, et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol. 2012;19(9):836–44. (author reply 844–835).CrossRefPubMed Abdollah F, Schmitges J, Sun M, et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol. 2012;19(9):836–44. (author reply 844–835).CrossRefPubMed
26.
Zurück zum Zitat Arcangeli G, Strigari L, Arcangeli S, et al. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;75(4):975–82.CrossRefPubMed Arcangeli G, Strigari L, Arcangeli S, et al. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;75(4):975–82.CrossRefPubMed
27.
Zurück zum Zitat Shao YH, Kim S, Moore DF, et al. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol. 2014;65(4):693–700.CrossRefPubMed Shao YH, Kim S, Moore DF, et al. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol. 2014;65(4):693–700.CrossRefPubMed
28.
Zurück zum Zitat Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13):2883–91.PubMedCentralCrossRefPubMed Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13):2883–91.PubMedCentralCrossRefPubMed
Metadaten
Titel
The role for surgeryin high-risk prostate cancer
verfasst von
Cécilia Lanchon
Shahrokh F. Shariat
Morgan Rouprêt, MD, PhD
Publikationsdatum
01.10.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 19-20/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-015-0389-y

Weitere Artikel der Ausgabe 19-20/2015

Wiener Medizinische Wochenschrift 19-20/2015 Zur Ausgabe